The Effect of Paroxetine on the Reduction of Migraine Frequency is Independent of Its Anxiolytic Effect.
OBJECTIVE
Anxiety is the most important precipitating factor of migraine attacks, and more than half of migraineurs have coexisting anxiety disorders. Paroxetine, an antidepressant, is one of the selective serotonin reuptake inhibitors (SSRIs) that has an anxiolytic effect, and is also known to be effective for migraine prophylaxis. The aim of this study was to determine the role of the anxiolytic effect of paroxetine on the prevention of migraine.


METHODS
This study investigated migraineurs with a general anxiety disorder who visited the neurological clinic. The following efficacy variables were assessed at baseline and after taking paroxetine (20 for 12 weeks: headache frequency, Hamilton Anxiety Rating Scale (HAM-A), Headache Management Self-Efficacy Scale (HMSE), and Headache Disability Inventory (HDI). The correlation between the headache responsiveness to paroxetine and improvement in anxiety levels was analyzed.


RESULTS
Twenty-four patients (aged 54.96+/-12.09 years, mean+/-SD) were included in this study. Paroxetine reduced headache frequency by 49.1% within 12 weeks (p<0.05 vs baseline). HAM-A and HMSE scores also showed an improvement, whereas there was no significant change in HDI score. The baseline HAM-A scores did not differ between paroxetine responders and nonresponders. In addition, the improvement in HAM-A score was not correlated with the reduction in headache frequency.


CONCLUSIONS
Paroxetine decreased the headache frequency and reduced anxiety levels. However, the anxiolytic effect of paroxetine was not correlated with the migraine prevention effect. These observation indicate that the anxiolytic effect of paroxetine does not contribute strongly to its prophylactic effect on migraine frequency in migraineurs with anxiety disorder.
Park
Hyun-Jung
HJ
Department of Neurology, Seoul National University College of Medicine, South Korea.
Lee
Soon-Tae
ST
Shim
Ji-Young
JY
Kim
Bomie
B
Hwang
Sun-Hee
SH
Kim
Sook-Hee
SH
Park
Jeong-Eun
JE
Park
Jong-Ha
JH
Jung
Se-Hee
SH
Ahn
Jin-Young
JY
Chu
Kon
K
Kim
Manho
M
Neurology. 1960 Feb;10:107-11
14409092
J R Soc Med. 1995 Jan;88(1):59
7884777
Headache. 1999 Nov-Dec;39(10):716-9
11279947
Arch Neurol. 1967 May;16(5):544-52
5297855
Headache. 2000 Sep;40(8):647-56
10971661
Cephalalgia. 1997 Feb;17(1):15-22
9051330
Headache. 1993 May;33(5):244-8
8320099
Arch Gen Psychiatry. 1990 Sep;47(9):849-53
2393343
Headache. 2005 Sep;45(8):1004-11
16109114
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002919
16034880
Br J Med Psychol. 1959;32(1):50-5
13638508
Headache. 1987 Mar;27(3):146-50
3597066
Pharmacol Rev. 1994 Jun;46(2):157-203
7938165
Cephalalgia. 2003 Jul;23(6):451-5
12807524
Cephalalgia. 2000 Jul;20(6):566-72
11075840
Neurology. 2001;56(6 Suppl 1):S4-12
11294954
Headache. 1998 May;38(5):356-65
9630788
Headache. 1999 Jan;39(1):28-32
15613191
Neurology. 1994 May;44(5):837-42
8190284
Trends Pharmacol Sci. 1989 Aug;10(8):307-9
2686127
Psychiatry Res. 1991 Apr;37(1):11-23
1862159
Brain. 1965 Dec;88(5):997-1010
5325360
Clin Pharmacol Ther. 1988 Jun;43(6):605-9
3378382
Cephalalgia. 2004;24 Suppl 1:9-160
14979299